Ferdinand KC, Rodriguez F, Nasser SA, et al. Cardiorenal metabolic syndrome and cardiometabolic risks in minority populations. Cardiorenal Med. 2014;4(1):1-11.
Graham G. Population-based approaches to understanding disparities in cardiovascular disease risk in the United States. Int J Gen Med. 2014;7:393-400.
Aiyer AN, Kip KE, Marroquin OC, Mulukutla SR, Edmundowicz D, Reis SE. Racial differences in coronary artery calcification are not attributed to differences in lipoprotein particle sizes: the Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) Study. Am Heart J. 2007;153(2):328-334.
Orakzai SH, Orakzai RH, Nasir K, Santos RD, Edmundowicz D, Budoff MJ, Blumenthal RS. Subclinical coronary atherosclerosis: racial profiling is necessary! Am Heart J. 2006;152(5):819-827.
Gadegbeku CA, Lea JP, Jamerson KA. Update on disparities in the pathophysiology and management of hypertension: focus on African Americans. Med Clin North Am. 2005;89(5):921-933.
Buckalew VM Jr, Freedman BI. Effects of race on albuminuria and risk of cardiovascular and kidney disease. Expert Rev Cardiovasc Ther. 2011;9(2):245-249
Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and Stroke Statistics−−2014 Update: A Report From the American Heart Association. Circulation. 2014;129(3):e28-e292.
World Health Organization. Diet, Nutrition and the Prevention of Chronic Diseases: Report of a Joint WHO/FAO Expert Consultation. Geneva, Switzerland: World Health Organization; 2003.
Wu F, Guo Y, Kowal P, et al. Prevalence of major chronic conditions among older Chinese adults: the Study on Global AGEing and adult health (SAGE) wave 1. PLoS One. 2013;8(9):e74176.
Alsheikh-Ali AA, Omar MI, Raal FJ, et al. Cardiovascular Risk Factor Burden in Africa and the Middle East: The Africa Middle East Cardiovascular Epidemiological (ACE) Study. PLoS One. 2014;9(8):e102830.
Kerr AJ, McLachlan A, Furness S, et al. The burden of modifiable cardiovascular risk factors in the coronary care unit by age, ethnicity, and socioeconomic status--PREDICT CVD-9. N Z Med J. 2008;121(1285):20-33.
Gunarathne A, Patel JV, Gammon B, Gill PS, Hughes EA, Lip GY. Ischemic stroke in South Asians: a review of the epidemiology, pathophysiology, and ethnicity-related clinical features. Stroke. 2009;40(6):e415-423.
Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780-800.
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.
NICE Guidelines 2011. Hypertension in adults: diagnosis and management. August 2011; 1-38
Brenner BM, Cooper ME, de Zeeuw D,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
de Zeeuw D, Ramjit D, Zhang Zet al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int. 2006;69:1675–1682.
Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: I–reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979a;242:2562–2571.
Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: II–mortality by race-sex and age. JAMA. 1979b;242:2572– 2577.
VA Cooperative 1970. VA Cooperative Study. Effects of treatment on morbidity in hypertension: II–results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143–1152.
VA Cooperative 1967. VA Cooperative Study. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA.1967;202:1028–1034.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Trial to Prevent Heart Attack Trial (ALLHAT). JAMA.2000;283:1967–1975.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997.
Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595–1608.
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004a;363:2022–2031.
Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163–2168.
Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.
Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol. 2004b;43:1047–1055.
Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–2431.
De acuerdo con la legislación Peruana es necesario confirmar que es usted es un profesional de la salud.
Portal web de Pfizer para Profesionales, donde podrá acceder a una amplia variedad de contenidos y servicios tales como:
Información de productos Pfizer
Seminarios Web en línea
Servicios e Información Médica
Educación Médica actualizada
Noticas médicas
Únicamente para profesionales de la salud
Confirmo que soy profesional de la salud residente en Perú.
Al hacer click en Aceptar, usted confirma que ha leído y acepta los términos y condiciones y autoriza el uso de sus datos personales para los fines descritos en el el aviso de privacidad.